Cas:952182-50-2 1-[(4-bromophenyl)methyl]-5-methyltriazole-4-carbonyl chloride manufacturer & supplier

We serve Chemical Name:1-[(4-bromophenyl)methyl]-5-methyltriazole-4-carbonyl chloride CAS:952182-50-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-[(4-bromophenyl)methyl]-5-methyltriazole-4-carbonyl chloride

Chemical Name:1-[(4-bromophenyl)methyl]-5-methyltriazole-4-carbonyl chloride
CAS.NO:952182-50-2
Synonyms:bromobenzylmethyltriazolecarbonylchloride;1-(4-bromo-benzyl)-5-methyl-1H-[1,2,3]triazole-4-carbonyl chloride
Molecular Formula:C11H9BrClN3O
Molecular Weight:314.56600
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:47.78000
Exact Mass:312.96200
LogP:2.77630

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like bromobenzylmethyltriazolecarbonylchloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(4-bromo-benzyl)-5-methyl-1H-[1,2,3]triazole-4-carbonyl chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,bromobenzylmethyltriazolecarbonylchloride Use and application,bromobenzylmethyltriazolecarbonylchloride technical grade,usp/ep/jp grade.


Related News: MSD – known as Merck in the US and Canada – is jointly developing Verquvo with Bayer. While MSD hold the commercial rights to the heart failure med in the US, Bayer has the exclusive commercial rights in the rest of the world. 1-(3-fluorophenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-carboxylic acid manufacturers Both were randomised, double-blinded, placebo-controlled trials in patients with moderate to severe autoantibody-positive SLE who were receiving standard therapy. 1H-Pyrazolo[3,4-d]thiazole-5-acetonitrile, 3-methyl-1-phenyl- suppliers The pivotal TULIP (Treatment of Uncontrolled Lupus via the Interferon Pathway) phase III programme includes two trials, TULIP-1 and TULIP-2, that evaluated the efficacy and safety of anifrolumab versus placebo. benzyl 2,3,6-tri-O-benzyl-4-O-(2,4-di-O-acetyl-3,6-di-O-benzyl-β-D-galactopyranosyl)-β-D-glucopyranoside vendor & factory.